Ribociclib
- Generic Name
- Ribociclib
- Brand Names
- Kisqali 200 Mg Daily Dose Carton, Kisqali Femara Co-pack, Kisqali
- Drug Type
- Small Molecule
- Chemical Formula
- C23H30N8O
- CAS Number
- 1211441-98-3
- Unique Ingredient Identifier
- TK8ERE8P56
- Background
Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring tha...
- Indication
用于联合芳香酶抑制剂或氟维司群治疗激素受体(HR)阳性、人表皮生长因子受体2(HER2)阴性的晚期或转移性乳腺癌成人患者。
- Associated Conditions
- Advanced Breast Cancer, Metastatic Breast Cancer
- Associated Therapies
- -
Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-01-30
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 376
- Registration Number
- NCT03822468
- Locations
- 🇺🇸
Southern Cancer Center PC, Mobile, Alabama, United States
🇺🇸Rocky Mountain Cancer Centers, Longmont, Colorado, United States
🇺🇸Nebraska Cancer Specialists, Omaha, Nebraska, United States
Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL
- Conditions
- Interventions
- First Posted Date
- 2018-11-14
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 45
- Registration Number
- NCT03740334
- Locations
- 🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸Nemours/Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-10-10
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 5101
- Registration Number
- NCT03701334
- Locations
- 🇺🇸
University of Alabama at Birmingham-Kirklin Clinic, Birmingham, Alabama, United States
🇺🇸Cancer Treatment Centers of America, Zion, Illinois, United States
🇺🇸Comprehensive Blood and Cancer, Bakersfield, California, United States
Ribociclib and Letrozole Treatment in Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-09-17
- Last Posted Date
- 2023-02-28
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 51
- Registration Number
- NCT03673124
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
🇺🇸Saint Vincent Hospital and Health Care Center, Inc., Indianapolis, Indiana, United States
🇺🇸The Ohio State Comprehensive Cancer Center, Columbus, Ohio, United States
Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.
- Conditions
- Interventions
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 327
- Registration Number
- NCT03671330
- Locations
- 🇨🇳
Novartis Investigative Site, Tianjin, China
Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-06-14
- Last Posted Date
- 2023-07-07
- Lead Sponsor
- German Breast Group
- Target Recruit Count
- 56
- Registration Number
- NCT03555877
- Locations
- 🇩🇪
Studienzentrum Onkologie Ravensburg, Ravensburg, Germany
Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer
- First Posted Date
- 2018-03-26
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 2
- Registration Number
- NCT03477396
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸City of Hope Corona, Corona, California, United States
🇺🇸City of Hope Rancho Cucamonga, Rancho Cucamonga, California, United States
Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant
- Conditions
- Interventions
- First Posted Date
- 2018-02-20
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 287
- Registration Number
- NCT03439046
- Locations
- 🇮🇹
Novartis Investigative Site, Napoli, Italy
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
- Conditions
- Interventions
- First Posted Date
- 2018-02-15
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 68
- Registration Number
- NCT03434262
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors
- Conditions
- Interventions
- First Posted Date
- 2017-12-29
- Last Posted Date
- 2021-08-27
- Lead Sponsor
- Pediatric Brain Tumor Consortium
- Target Recruit Count
- 22
- Registration Number
- NCT03387020
- Locations
- 🇺🇸
National Cancer Institute Pediatric Oncology Branch, Bethesda, Maryland, United States
🇺🇸St. Jude Children Research Hospital, Memphis, Tennessee, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.